Baxter International Inc

Baxter International Inc. has announced a $590 million 2024 dividend payout, a 10.34% reduction from the previous year, but its dividend yield has increased to 3.57%.

Baxter International’s stock price has been highly volatile, with a plummeting price-to-earnings ratio and a significant drop in dividend payout, raising concerns about the company’s financial health and potential value trap.

Baxter’s Q1 revenue has exceeded expectations, driven by a strategic shift that is paying off, sending its stock price on an upward trend.

Baxter International exceeded Q1 2025 earnings projections, boosting its full-year outlook and sending its stock price soaring.

Baxter International Inc. will present at the Bank of America Securities 2025 Health Care Conference, showcasing its new products and upcoming quarterly earnings.

Baxter International’s stock price has been stable, with a current price of $28.14 USD, and a 52-week range of $26.25 to $41.18 USD.

Baxter International’s stock price has stabilized after a 22% decline, with analysts remaining optimistic about the company’s prospects and predicting a potential 43% upside.

Baxter International has launched its revolutionary Hemopatch Sealing Hemostat in Europe, a breakthrough innovation that empowers surgeons to control bleeding and prevent leakage with unprecedented precision.

Baxter International has launched its revolutionary Hemopatch Sealing Hemostat in Europe, a breakthrough product that empowers surgeons to control bleeding and prevent leakage with unprecedented precision.

Baxter International’s stock value has surged, outperforming the healthcare sector, driven by strong Q4 results and the success of its innovative medical device, the Novum IQ pump.